Data / Public companies / SIC 2834: Pharmaceutical preparations / Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.: revenue, net income and total assets from its latest annual report
Arrowhead Pharmaceuticals, Inc. reported revenue of $829.4 million, a net loss of $1.6 million and total assets of $1.39 billion for the fiscal year ended September 30, 2025, in its annual report (10-K) filed with the SEC on November 25, 2025. It ranks 38th by revenue of 272 companies in SIC 2834, pharmaceutical preparations.
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- SEC central index key (CIK)
- 879407
- Industry
- SIC 2834, Pharmaceutical preparations
- Business address (city and state)
- Pasadena, California
- Incorporated in
- Delaware
- Filer category
- Large accelerated filer
- Fiscal year ends
- September 30
- Latest annual report
- 10-K filed November 25, 2025
- Annual and quarterly reports in the data
- 1 annual, 4 quarterly
Financials for the fiscal year ended September 30, 2025
As filed, in US dollars. The prior year value is the comparison column in the same report.
| Item | This year | Prior year | Change | Source |
|---|---|---|---|---|
| Revenue | $829,448,000 | $3,551,000 | 23,258.2% | sec.gov |
| Operating income | $98,346,000 | Not listed | Not listed | sec.gov |
| Net income | $-1,631,000 | $-599,493,000 | 99.7% | sec.gov |
| Total assets | $1,385,295,000 | $1,139,802,000 | 21.5% | sec.gov |
| Stockholders' equity | $466,052,000 | Not listed | Not listed | sec.gov |
| Cash and cash equivalents | $226,548,000 | Not listed | Not listed | sec.gov |
How it compares
- Net margin (net income over revenue)
- -0.2%
- Revenue change on the prior year
- 23258.2%
- Revenue rank in SIC 2834
- 38th of 272
- Revenue rank in California
- 220th of 662
- Revenue rank among all companies in the data
- 1,794th of 4,486
Companies next to it by revenue in SIC 2834
Pharmaceutical preparations, from the same data.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. | West Conshohocken, PA | $958.4 million | $-288,284,000 | $1.26 billion | 432.1% |
| Ionis Pharmaceuticals Inc | Carlsbad, CA | $943.7 million | $-381,387,000 | $3.52 billion | 33.8% |
| Ani Pharmaceuticals Inc | Baudette, MN | $883.4 million | $78.3 million | $1.44 billion | 43.8% |
| Harmony Biosciences Holdings, Inc. | Plymouth Meeting, PA | $868.5 million | $158.7 million | $1.27 billion | 21.5% |
| Collegium Pharmaceutical, Inc | Stoughton, MA | $780.6 million | $62.9 million | $1.66 billion | 23.6% |
| Corcept Therapeutics Inc | Redwood City, CA | $761.4 million | $99.7 million | $836.7 million | 12.8% |
| Emergent Biosolutions Inc. | Gaithersburg, MD | $742.9 million | Not listed | Not listed | -28.8% |
| Pacira Biosciences, Inc. | Brisbane, CA | $726.4 million | $7 million | $1.26 billion | 3.6% |
Updated November 25, 2025. Read from SEC Financial Statement Data Sets, filing 0000879407-25-000029. Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.